We bring together individuals with the KRAS-variant to share their stories, learn from one other, and offer support.
During the summer of 2009, Tina Kelly noticed two pea-sized lumps in her right breast. Feeling strong and having plenty of energy, she thought for sure they were benign fibroids, which she had had previously. Just to be safe, she visited her physician. When a deeper scan revealed a substantial tumor in her right breast, Tina was utterly blindsided.read more
I had a wonderful conversation with a woman who participated in the first MiraKind study. While I always enjoy speaking with study participants, I had very mixed emotions about this conversation, because I was discussing her KRAS-variant results with her – and she is positive.read more
Although much of the world has accepted that GWAS studies, which use an outdated technology looking at large amounts of data, have failed to find any functional mutations, this approach has twice been used to try and refute the validity of the KRAS-variant.read more
We are embarking on a study to explore how breast cancer management strategies (e.g., chemotherapy, surgery, hormones) that are used to treat breast cancer, impact breast cancer risk for women with the KRAS-variant.read more